Page 82 - EF600

Menopausia y madurez han ido gestando durante años tras la pérdida de pro- ducción estrogénica, que tiene un factor protector, y de ahí la importancia de instaurar medidas saludables años antes para prevenir este tipo de patologías. (Es- tas enfermedades se tratarán en el tema 11 de este curso.) Si se desea ampliar conocimientos sobre estos con- ceptos, la Sociedad Española de Farmacia Clínica, Fami- liar y Comunitaria (SEFAC) tiene a disposición del intere- sado el curso M+40, en el que se trata ampliamente todo lo referente a estas etapas de la vida de la mujer23. l Bibliografía 1. Sánchez-Borrego R, Mendoza N. Menoguía Sofocos. ¿Estoy pasando la menopausia? Tratamientos: ¿qué aporta la tibolona? AEEM, 2013 \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\[consultado en abril de 2021\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\]. Disponible en: https://aeem.es/ download/sofocos-estoy-pasando-la-menopausia-tratamientos-que- aporta-la-tibolona/ 2. Harlow S. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfished agenda of staging reproductive aging. Menopause. 2012; 14(4): 1-9. 3. Burger HG, Hale GE, Dennerstein L, Robertson DM. Cycle and hormone changes during perimenopause: the key role of ovarian function. Menopause. 2008; 15(4 Pt 1): 603-612. 4. Stearns V, Ullmer L, López JF, Smith Y, Isaacs C, Hayes DF. Hot flushes. Lancet. 2002; 360: 1.851-1.861. 5. Harlow S, Gass M, Hall J, Lobo R, Maki P, Rebar R, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012; 19(4): 387-395. 6. Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Johnston S, et al. Managing menopause. J Obstet Gynaecol Can. 2014; 36(9): 830-838. 7. Palacios S, Ferrer-Barriendos J, Parrilla JJ, Castelo-Branco C, Manubens M, Alverich X, et al. Calidad de vida relacionada con la salud en la mujer española durante la perimenopausia y posmenopausia. Desarrollo y validación de la Escala Cervantes. Med Clin (Barc). 2004; 122(6): 205-211. 8. Aranceta J, Serra Majem L, Arija V, Gil A, Martínez de Vitoria E, Ortega R. Objetivos nutricionales para la población española: consenso de la Sociedad Española de Nutrición Comunitaria 2011. Rev Esp Nutr Comunitaria. 2011; 17(4): 178-199. 9. Deng X, Song Y, Manson J, Signorello L, Zhang S, Shrubsole M, et al. Magnesium, vitamin D status and mortality: results from US National Health and Nutrition Examination Survey (NHANES) 2001 to 2006 and NHANES III. BMC Med. 2019; 14(4): 4-5. 10. Rodríguez Alcalá L. El ejercicio físico en la mujer durante la perimenopausia y la posmenopausia. Documento de información a las mujeres. Menoguía AEEM. 2016; 36-44. 11. Hairi HA, Shuid AN, Ibrahim NI, Jamal JA, Mohamed N, Mohamed IN. The effects and action mechanisms of phytoestrogens on vasomotor symptoms during menopausal transition: thermoregulatory mechanism. Curr Drug Targets. 2019; 20(2): 192-200. 12. Arriaza E, Arévalo MC, Grandas MA, Olleros T. Eficacia de Cimicifuga racemosa para el tratamiento de la clínica vasomotora y psíquica en pacientes menopáusicas. Prog Obstet Ginecol. 2008; 51(1): 20-27. 13. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Gynaecology and Fertility Group, editor. Cochrane Database Syst Rev. 2004 \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\[consultado el 24 de abril de 2021\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\]. Disponible en: http://doi.wiley.com/10.1002/14651858.CD002978.pub2 14. Amador N, Amariles P, Baixauli VJ, Benrimoj SI, Climent MT, Colomer V, et al. Protocolos de indicación farmacéutica y criterios de derivación al médico en síntomas menores. Granada: Técnica Avicam; 2018. p. 179-186. 15. Comino R, Coronado PJ, Cararach M, Nieto A, Martínez-Escoriza JC, Salamanca A, et al. Spanish consensus on vulvar disorders in postmenopausal women. Maturitas. 2015; 80(2): 226-233. 16. Nappi RE, Palacios S, Panay N, Particco M, Krychman ML. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. Climacteric. 2016; 19(2): 188-197. 17. Beerepoot M, Geerlings S. Non-antibiotic prophylaxis for urinary tract infections. Pathogens. 2016; 5(2): 36. 18. Salinas Casado J, Luján Galán M, Esteban Fuertes M, Vírseda Chamorro M. Papel de la D-manosa en el manejo de las infecciones urinarias. Editorial Selene, 2016. Disponible en: https://arafarma.com/ web/wp-content/uploads/2015/10/papel-de-la-d-manosa-en-el- manejo-de-las-itu.pdf 19. Pimentel CL, Puig L. Alteraciones dermatológicas en la menopausia. Farmacia Profesional. 2003; 17(9): 84-91. 20. Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017; 77(1): 136-141. 21. Craig J, Nichols K, Nichols J, Caffery B, Dua H, Joo CK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017; 15(3): 276-283. 22. Sociedad Española de Superficie Ocular (SESOC) y THEA. Guías españolas para el tratamiento de la enfermedad del ojo seco. Documento de consenso. Disponible en: http://www. lasuperficieocular. com/resources/documents/guias_ojo_seco SESOC_THEA.pdf 23. Climent MT, Mera I, Domínguez B, Andraca L, Caelles N. Atención de la perimenopausia en la farmacia comunitaria. SEFAC, 2020. Nota de Redacción: La figura 1 puede consultarse en la versión web de este artículo (www.elfarmaceutico.es) y en www.aulamayo.com A ¡Acceda a www.aulamayofarmacia.com para seguir el curso! 80 junio 2021 – el farmacéutico n.o 600 ©2021 Ediciones Mayo, S.A. Todos los derechos reservados